Reevaluating Statins: Cardiovascular Protection and Cognitive Health

Since the introduction of Lovastatin in 1987, statins have been central to

cholesterol management and cardiovascular disease prevention. I was an early

adopter, optimistic that lowering cholesterol would reduce heart attacks and other

cardiovascular events. With the release of the second statin, Pravastatin, in 1991,

new research highlighted that inflammation, not just cholesterol, was a key driver

of vascular and cardiovascular disease. Statins were marketed not only as

cholesterol-lowering agents but also as anti-inflammatory drugs, suggesting they

could address multiple aspects of coronary artery disease.

However, as evidence has evolved, so too has the understanding of how

inflammation underlies many chronic diseases. Pro-inflammatory conditions like

Diabetes, Hypertension, and other metabolic disorders affect all organs,

particularly the heart and brain. Over time, I began to see that an anti-inflammatory

approach—one focused on reducing underlying metabolic and inflammatory

drivers—might be a more sustainable path for long-term cardiovascular health.

Given the various side effects associated with statins, including potential impacts

on brain health, less toxic anti-inflammatory therapies may offer a safer option for

managing cardiovascular risk.

Cholesterol’s Role in the Brain: From Newborn to Aging Adult

In newborns and toddlers, cholesterol levels are naturally low, typically ranging

from 70 to 100 mg/dL—much lower than typical adult levels. Yet, the brain

undergoes rapid growth and development during this time, supported by its own

production of cholesterol. Unlike other organs, the brain is isolated by the blood-

brain barrier, which prevents cholesterol from crossing in either direction. This

means the brain relies exclusively on local cholesterol production by astrocytes to

meet its needs for growth, cell membrane formation, and early learning. While

80% of the body’s total cholesterol is produced in the liver, the brain synthesizes its

own cholesterol independently to maintain neural health and synaptic function. At

this young age, the risks from pro-inflammatory conditions are also typically low,

allowing the brain to develop effectively with low serum cholesterol levels without

impact on cognitive health.

As we age, however, the brain becomes increasingly dependent on maintaining

adequate cholesterol synthesis for cognitive function. The capacity for cholesterol

production in the brain declines with age, and pro-inflammatory conditions like

Diabetes and Hypertension—which increase in frequency as we age—can disrupt

this synthesis, potentially impacting cognitive resilience. This shift underscores the

importance of preserving cholesterol production as a protective factor for the aging

brain.

Statins and Absolute Risk Reduction

Statins do reduce cardiovascular risk, but their overall benefit is modest. Across all

groups—primary prevention (low-risk individuals) and secondary prevention

(high-risk individuals)—statins lower the risk of cardiovascular events by about 2-

3% over five years. In other words, for every 100 people on statins, 2 to 3

cardiovascular events are prevented on average. When it comes to reducing deaths

from any cause, the effect is even smaller, with an absolute reduction of only 0.5-

1.5%. Given these numbers, the potential benefits of lifelong statin use, especially

in low-risk individuals, have become less compelling to me as a prescriber.

Statins, Cognition, and Diabetes Risk

Questions about statins’ effects on cognition have become increasingly relevant. A

2015 study in JAMA Internal Medicine linked statins with memory issues,

particularly in those with pre-existing cognitive decline. More recent data indicate

that high-intensity statin therapy may increase the risk of developing diabetes or

worsening insulin resistance by 36%, a metabolic disease strongly tied to cognitive

decline. This paradox—where a drug that can prevent heart disease may

inadvertently contribute to cognitive issues by provoking another disease—has led

me to reevaluate its broad application, particularly in older adults at lower

cardiovascular risk.

Balancing Risks and Benefits

Some argue that statins’ cardiovascular benefits outweigh potential cognitive risks,

but for many patients, especially those without a history of cardiovascular events,

the modest reduction in cardiovascular mortality (~3%) must be weighed against

quality of life. In my humble opinion, most patients would prefer to avoid any

further cognitive decline or impact on day-to-day activities and accept the slight

cardiovascular risk that statins seem to reduce. In patients already experiencing

cognitive decline, a “statin holiday” of about 30 days can help determine if

memory improves without the medication. I have often used this approach with

good results.

Prioritizing Brain Health Holistically

For those concerned with cognitive health, lifestyle changes provide valuable

support. Regular exercise, an anti-inflammatory diet, and supplements like vitamin

D and fish oil benefit both heart and brain health. B vitamins and Ashwagandha

may also provide benefits. Reducing alcohol intake, managing stress, and

prioritizing sleep are additional measures that support long-term cognitive

resilience.

Ultimately, in cases of cognitive decline, a careful reassessment of statin use is

warranted. Statins do not prevent dementia, and for many older adults, focusing on

lifestyle adjustments and less toxic anti-inflammatory therapies may offer a safer,

more sustainable approach to both cognitive and cardiovascular health.